If you would like more information about the profile please click
. You will be directed to a new page where you will need
to provide some information about yourself/your business cooperation needs and submit
your expression of interest in the profile . A Network Partner will then contact
you to discuss your interest in greater detail.
A bio-venture Korean SME has developed first-in-class drug synthesis since established in 2015, and the company represents new drug candidates that have an efficiency of relief on Nonalcoholic Steatohepatitis, Liver Fibrosis, and Liver Cirrhosis, which are called Adenosine Receptor Antagonist. The company came up with the idea due to lack of pharmaceutical treatment for NASH. The company is, thus, open to take the partnership of license and commercial agreement with technical assistant.
A Korean company established in 2015 is based on research of pharmaceutical products and drugs.
Nonalcoholic fatty liver disease (NAFLD) is caused by obesity and diabetes, and it includes simple steatosis, Nonalcoholic Steatohepatitis (NASH) along with liver cell disruption, inflammation, and fibrosis, and Cirrhosis of liver.
There is approximately 20~30% of population suffering from NAFLD due to geriatric diseases, and NASH is caused approximately 10~20% of NAFLD patients, and 9~25% of them suffers from liver cirrhosis and liver cancer eventually.
Not all of patients has NASH, however in case of causing it, it results in death due to complication. Therefore, there is point that stage of NASH has to be cured for NAFLD.
The existing new drug candidate materials have 72% and 85% of sequence homology to human’s receptors in case of rat and sheep respectively, which shows a low rate of receptors. In spite of excellent results of animal test on new drug materials, it could not be examined the same result on clinical trial. However, the company examined the equal binding affinity with human regardless of species.
The company is looking for partners who would solve the problems on the existing materials and develop new treatment for non-alcoholic steatohepatitis and make them sued in pharmaceutical industry under commercial agreement with technical assistance and license agreement.
The Korean company is seeking for the experts as the partners in order to collaborate on the work of developing new drug candidates as a treatment for non-alcoholic fatty liver diseases. The technology is highly specific and detailed, so the partners should have capabilities of studying the pharmaceutical products and drugs.
- Type of partner sought: Companies have professional perspectives on pharmaceutical materials.
- Specific area of activity of the partner: The partners should be specialized in the industry of pharmaceutical, and also interested in developing new drug candidates.
- Task to be performed: The company has on-going research of pharmaceutical products and drugs related to non-alcoholic liver diseases, and they would like to focus on developing new medication under commercial agreement with technical assistant, and license agreement would make the new developed drugs be used in pharmaceutical industry.